Enlivex Therapeutics Ltd
NASDAQ:ENLV
Income Statement
Earnings Waterfall
Enlivex Therapeutics Ltd
Revenue
|
0
USD
|
Operating Expenses
|
-25.2m
USD
|
Operating Income
|
-25.2m
USD
|
Other Expenses
|
-3.9m
USD
|
Net Income
|
-29.1m
USD
|
Income Statement
Enlivex Therapeutics Ltd
Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||||||||||||||||||||||||
Operating Expenses |
(7)
|
(10)
|
(12)
|
(14)
|
(15)
|
(17)
|
(17)
|
(18)
|
(16)
|
(14)
|
(12)
|
(8)
|
(6)
|
(4)
|
(4)
|
(4)
|
(2)
|
(3)
|
(4)
|
(5)
|
(9)
|
(8)
|
(9)
|
(9)
|
(10)
|
(12)
|
(13)
|
(15)
|
(19)
|
(22)
|
(24)
|
(26)
|
(26)
|
(26)
|
(27)
|
(27)
|
(25)
|
|
Selling, General & Administrative |
(3)
|
(4)
|
(5)
|
(6)
|
(7)
|
(7)
|
(8)
|
(7)
|
(6)
|
(5)
|
(4)
|
(4)
|
(3)
|
(2)
|
(2)
|
(1)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(4)
|
(5)
|
(5)
|
(5)
|
(6)
|
(7)
|
(7)
|
(8)
|
(7)
|
(7)
|
(7)
|
(7)
|
(6)
|
|
Research & Development |
(4)
|
(6)
|
(7)
|
(8)
|
(8)
|
(8)
|
(7)
|
(9)
|
(9)
|
(8)
|
(7)
|
(4)
|
(3)
|
(2)
|
(2)
|
(3)
|
(0)
|
(3)
|
(3)
|
(4)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(7)
|
(8)
|
(10)
|
(12)
|
(15)
|
(17)
|
(18)
|
(18)
|
(19)
|
(20)
|
(20)
|
(18)
|
|
Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
|
Other Operating Expenses |
0
|
0
|
0
|
(0)
|
(1)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
0
|
0
|
0
|
0
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(7)
N/A
|
(10)
-38%
|
(12)
-27%
|
(14)
-12%
|
(15)
-12%
|
(17)
-8%
|
(17)
+0%
|
(18)
-6%
|
(16)
+10%
|
(14)
+12%
|
(12)
+15%
|
(8)
+29%
|
(6)
+29%
|
(4)
+25%
|
(4)
+18%
|
(4)
-4%
|
(2)
+45%
|
(3)
-58%
|
(4)
-14%
|
(5)
-23%
|
(9)
-85%
|
(8)
+5%
|
(9)
-11%
|
(9)
+2%
|
(10)
-10%
|
(12)
-19%
|
(13)
-14%
|
(15)
-14%
|
(19)
-27%
|
(22)
-13%
|
(24)
-9%
|
(26)
-8%
|
(26)
0%
|
(26)
-1%
|
(27)
-3%
|
(27)
+0%
|
(25)
+7%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
(0)
|
(1)
|
(1)
|
(1)
|
1
|
(0)
|
0
|
(2)
|
(3)
|
(1)
|
(0)
|
5
|
(1)
|
(5)
|
(6)
|
(5)
|
(5)
|
(1)
|
(1)
|
0
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(4)
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
3
|
3
|
3
|
(0)
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(7)
N/A
|
(10)
-38%
|
(12)
-27%
|
(14)
-12%
|
(15)
-12%
|
(17)
-8%
|
(17)
0%
|
(18)
-6%
|
(16)
+10%
|
(14)
+12%
|
(12)
+15%
|
(8)
+29%
|
(6)
+30%
|
(4)
+27%
|
(3)
+26%
|
(3)
-1%
|
(2)
+34%
|
(4)
-77%
|
(5)
-25%
|
(6)
-28%
|
(9)
-57%
|
(8)
+20%
|
(9)
-21%
|
(9)
+3%
|
(12)
-34%
|
(14)
-20%
|
(14)
0%
|
(16)
-9%
|
(14)
+7%
|
(20)
-35%
|
(26)
-35%
|
(29)
-9%
|
(31)
-9%
|
(30)
+3%
|
(27)
+10%
|
(27)
-1%
|
(29)
-7%
|
|
Net Income | ||||||||||||||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(7)
|
(10)
|
(12)
|
(14)
|
(15)
|
(17)
|
(17)
|
(18)
|
(16)
|
(14)
|
(12)
|
(8)
|
(6)
|
(4)
|
(3)
|
(3)
|
(2)
|
(4)
|
(5)
|
(6)
|
(9)
|
(8)
|
(9)
|
(9)
|
(12)
|
(14)
|
(14)
|
(16)
|
(14)
|
(20)
|
(26)
|
(29)
|
(31)
|
(30)
|
(27)
|
(27)
|
(29)
|
|
Net Income (Common) |
(7)
N/A
|
(10)
-38%
|
(12)
-27%
|
(14)
-12%
|
(15)
-12%
|
(17)
-8%
|
(17)
N/A
|
(18)
-7%
|
(16)
+10%
|
(14)
+12%
|
(12)
+15%
|
(8)
+30%
|
(6)
+30%
|
(4)
+28%
|
(3)
+26%
|
(3)
-1%
|
(2)
+35%
|
(4)
-78%
|
(5)
-25%
|
(6)
-28%
|
(10)
-60%
|
(8)
+20%
|
(9)
-20%
|
(9)
+3%
|
(12)
-31%
|
(14)
-20%
|
(14)
0%
|
(16)
-9%
|
(14)
+7%
|
(20)
-35%
|
(26)
-35%
|
(29)
-9%
|
(31)
-9%
|
(30)
+3%
|
(27)
+10%
|
(27)
-1%
|
(29)
-7%
|
|
EPS (Diluted) |
-19.5
N/A
|
-26.86
-38%
|
-34.02
-27%
|
-38.02
-12%
|
-42.69
-12%
|
-46.27
-8%
|
-40.63
+12%
|
-43.36
-7%
|
-40.04
+8%
|
-34.39
+14%
|
-29.36
+15%
|
-20.09
+32%
|
-14.51
+28%
|
-9.77
+33%
|
-7.27
+26%
|
-7.34
-1%
|
-5.02
+32%
|
-7.81
-56%
|
-0.46
+94%
|
-0.58
-26%
|
-1.11
-91%
|
-0.67
+40%
|
-0.69
-3%
|
-0.67
+3%
|
-0.9
-34%
|
-0.86
+4%
|
-0.78
+9%
|
-0.85
-9%
|
-0.81
+5%
|
-1.07
-32%
|
-1.44
-35%
|
-1.56
-8%
|
-1.69
-8%
|
-1.63
+4%
|
-1.46
+10%
|
-1.47
-1%
|
-1.56
-6%
|